This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Investors Need to Take Advantage of These 2 Consumer Staples Stocks Now
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Factors Likely to Support Clorox's (CLX) Earnings Beat in Q2
by Zacks Equity Research
Clorox's (CLX) Q2 results are likely to reflect gains from strong demand, cost savings, improved productivity and pricing actions. The company's IGNITE strategy also bodes well.
Is Clorox (CLX) Outperforming Other Consumer Staples Stocks This Year?
by Zacks Equity Research
Here is how Clorox (CLX) and Corteva, Inc. (CTVA) have performed compared to their sector so far this year.
Clorox (CLX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Clorox (CLX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Colgate (CL) is Well-Poised for Earnings Beat in Q4
by Zacks Equity Research
Colgate's (CL) Q4 results are expected to reflect gains from strong consumer demand, innovation, brand strength, and focus on premiumization and digital transformation.
Want Better Returns? Don?t Ignore These 2 Consumer Staples Stocks Set to Beat Earnings
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Time to Buy These Consumer Staples Stocks Before Earnings?
by Shaun Pruitt
As we progress through earnings season, investors may want to pay attention to the Consumer Staples sector as there are quite a few stocks that could beat earnings expectations.
How to Find Strong Consumer Staples Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
These 2 Consumer Staples Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Will Colgate's (CL) Growth Strategies Aid Amid Cost Woes?
by Zacks Equity Research
Colgate (CL) is on track with its stringent pricing actions and accelerated revenue growth management plans. Higher raw material and logistic costs continue to hurt.
Here's Why You Should Hold on to Clorox (CLX) Stock Now
by Zacks Equity Research
Despite inflation concerns, Clorox (CLX) looks well poised to drive growth in the future on the back of solid demand, pricing actions, cost savings efforts and other growth strategies.
Clorox (CLX) Up 8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Clorox (CLX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
5 Soaps & Cleaning Materials Stocks Showing Potential Amid Hardships
by Rajani Lohia
The soap and cleaning materials industry battles headwinds from elevated logistics, input and manufacturing costs. Innovation, digital growth and brand building are likely to drive players like PG, RBGLY, HENKY, CHD and CLX.
Clorox (CLX) Tops Q1 Earnings & Sales Estimates, Retains View
by Zacks Equity Research
Clorox's (CLX) Q1 results reflect gains from brand strength, strong execution, cost savings and a favorable price mix despite lower volumes.
Clorox (CLX) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Clorox (CLX) delivered earnings and revenue surprises of 27.40% and 3.26%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
What Awaits The Estee Lauder Companies (EL) in Q1 Earnings?
by Zacks Equity Research
The Estee Lauder Companies (EL) Q1 performance will likely reflect adverse impacts from record inflation and supply chain disruptions. That said, strength in online sales is a breather.
Nu Skin (NUS) Queued for Q3 Earnings: Things to Consider
by Zacks Equity Research
Nu Skin's (NUS) Q3 performance will likely reflect continued economic uncertainty, prolonged COVID-associated factors, unfavorable currency rates and geopolitical conflicts.
Kellogg's (K) Q3 Earnings Upcoming: Here's All You Should Note
by Zacks Equity Research
Kellogg's (K) third-quarter 2022 results are likely to reflect gains from the company's revenue growth management actions, whereas cost inflation and supply-chain bottlenecks are likely to have been a concern.
Sysco's (SYY) Q1 Earnings Upcoming: Key Factors to Note
by Zacks Equity Research
Sysco's (SYY) first-quarter fiscal 2023 results are likely to reflect gains from the Recipe for Growth program and a diversified model, whereas high costs might have been a concern.
Service Corporation (SCI) to Report Q3 Earnings: Things to Note
by Zacks Equity Research
Service Corporation's (SCI) third-quarter 2022 performance will likely reflect the adverse impact of rising inflationary pressure. Strength in the funeral segment has been an upside.
Factors Likely to Influence Molson Coors' (TAP) Earnings in Q3
by Zacks Equity Research
Molson Coors' (TAP) Q3 results are likely to reflect gains from positive pricing and favorable brand and channel mix stemming from portfolio premiumization and reduced on-premise channel restrictions.
Here's Why Clorox (CLX) is Poised to Top Q1 Earnings Estimates
by Zacks Equity Research
Clorox's (CLX) first-quarter fiscal 2023 results are likely to reflect gains from the IGNITE strategy and pricing actions, whereas elevated inflation concerns are likely to have acted as deterrents.
Colgate-Palmolive (CL) Q3 Earnings Meet Estimates
by Zacks Equity Research
Colgate-Palmolive (CL) delivered earnings and revenue surprises of 0% and 0.97%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Can Colgate (CL) Beat Q3 Earnings Estimates Amid Cost Woes?
by Zacks Equity Research
Colgate's (CL) Q3 results are expected to reflect gains from strong demand, brand strength, innovation and digital growth, offset by higher raw material and logistic costs.
Clorox (CLX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Clorox (CLX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.